February 7, 2019 5:31pm
The sector was already on edge as quarterly LPS (loss-per-share) results i.e. earnings began today!
Out and about: Solid Biosciences (SLDB -$15.15 or -67.82%) craters with disappointing news from its first gene therapy clinical trial as Sangamo Therapeutics’ (SGMO -$3.71) early-stage studies failed to demonstrate the benefit of two gene-editing compounds joining its fellow “editors” – CRSP (-$2.85), EDIT (-$1.67) and NTLA (-$1.07) in the run to yet another bottom
Quarterly results (in body of content): Organovo Holdings (ONVO +$0.01) and Alnylam Pharmaceuticals (ALNY -$0.96)
Pre-open Indication: 7 HITs and 1 MISS (by +$0.01)
It’s not hard to be right so often, I start early, stay involved and leave late and am NOT indentured to ANY financial institution!
Members only. Please login.